Regulation & Industry news
Careers
The new hire brings more than two decades’ experience managing complex cross-border disputes in life sciences and technology, including most recently at the Unified Patent Court. 18 September 2026
Regulation & Industry
Featuring interviews with dozens of lawyers, LSIPR published a five-part deep dive into the levers driving a surge in life sciences dealmaking. Author Marisa Woutersen discovered where buyers are placing their bets, what sellers can do to make themselves 'acquisition-ready', and why IP can make or break a deal. 17 September 2026
Pharma
A medicine reaching the end of its primary patent term does not necessarily mean the market is open to generics. The complex patent landscape surrounding semaglutide shows how secondary patents covering indications, formulations and manufacturing processes can extend competitive barriers—and why careful freedom-to-operate analysis is critical before launch, says Ana Neves of Inventa. 16 September 2026
Regulation & Industry
Pitching for business has always been a partner’s game. One in-house team decided junior lawyers needed a seat at the table, building a programme to close an “industry-wide gap” in vital experience. Marisa Woutersen spoke with organisers Regeneron and associates from A&O Shearman, Hoyng Rokh Monegier, and Bristows, who stepped up to ‘sell’ their firms. 14 September 2026
Regulation & Industry
For biotech companies, promising science is no longer enough to attract a pharma buyer. Lawyers from Morrison Foerster, Polsinelli, Morgan Lewis and Dechert explain what makes an acquisition target truly deal-ready. Marisa Woutersen explores what companies should get right before a potential acquirer comes knocking. 11 September 2026
Regulation & Industry
Clarity from the Enlarged Board of Appeal for when patent descriptions must be amended to reflect changes to the claims has finally arrived. LSIPR outlines G 1/25, the debate that led to the referral and the EPC provisions at the heart of the ruling. 4 September 2026
Regulation & Industry
Lawmakers support a bill that would place guardrails on lawyers’ use of generative AI for court filings, in a bid to clamp down on AI ‘hallucinations’ and inaccuracies. 4 September 2026
Pharma
Turkish regulators are investigating the drugmaker over its efforts to protect its drug from generic rivals—conduct that may sound familiar to European competition watchers. 27 August 2026
Regulation & Industry
Dozens of new and revised guidances could make it faster and less costly to bring generics to market, as the US ramps up pressure on drug prices. 27 August 2026
Regulation & Industry
While promising science draws in buyers, intellectual property determines the price, terms, and viability of an agreement. LSIPR digs into what investors are looking for—and the biggest turn-offs that destroy a deal. 25 August 2026